Author of

• 10801

  +

  P1.11 - Poster Session 1 - NSCLC Novel Therapies (ID 208)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10802

    +

    P1.11-001 - Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) related interstitial lung disease in Taiwanese patients with non-small cell lung cancer (ID 261)

    09:30 - 09:30  |  Author(s): C. Chiang
    • Abstract

    Background
    In the recent years, it has been shown that epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), gefitinib or erlotinib, can provide significant benefit to patients with advanced non-small cell lung cancer (NSCLC). A major concern during EGFR-TKI treatment is the development of interstitial lung disease (ILD). The incidence and clinical characteristics of ILD associated with EGFR-TKIs in Taiwanese patients are less well defined.

    Methods
    Patients with advanced NSCLC in the Taipei Veterans General Hospital were screened and patients who had received EGFR-TKIs were enrolled in this study. The clinical information including medical records and chest images were reviewed. The diagnosis of EGFR-TKI related ILD was confirmed by two pulmonologists according to previously published criteria. Association between ILD development and clinical factors was evaluated.

    Results
    From February 2008 to July 2012, a total of 1214 patients who received EGFR-TKI as single therapy for NSCLC were screened. Patients who developed severe ILD and needed hospitalization (grade 3-5) were included. Consequently, 9 of 1214 patients (0.7%) were diagnosed to have severe EGFR-TKI related ILD. The median age of the patients with ILD was 61.0 years and 6 were male (66.7%). The median time interval from EGFR-TKIs use to onest of ILD was 31 days (range: 10-75 days). The most common symptom of EGFR-TKIs related ILD was dyspnea (88.9%). The most common radiological manifestation was bilateral ground glass opacity (GGO), which was noted in 5 patients (55.6%). All patients discontinued EGFR-TKIs immediately when ILD was suspected and 8 patients (88.9%) received systemic steroids. Six of nine patients (67%) patients died from ILD.

    Conclusion
    EGFR-TKIs, both gefitinib and erlotinib may cause fatal ILD in Taiwanese NSCLC patients. Physicians should be aware of this rare but severe side effect of EGFR-TKI and monitor this pulmonary toxicity closely.